Literature DB >> 7510623

Treatment recommendations for osteosarcoma and adult soft tissue sarcomas.

P Picci1, S Ferrari, G Bacci, F Gherlinzoni.   

Abstract

During the past 20 years, dramatic improvements have been obtained in the treatment of localised osteosarcoma of the extremities, both in the rates of disease-free survival and in quality of life. Twenty years ago 80 to 90% of the patients died, in spite of mutilating surgery, but now about 75% survive and avoid the necessity of amputation. This is due to the introduction of very effective combined treatments, mostly also using preoperative chemotherapy. One of the major issues is that of intensive preoperative chemotherapy, which improves both limb salvage and survival. A multidisciplinary approach is necessary to obtain good results. When the role of adjuvant or neoadjuvant chemotherapy is not accurately defined for soft tissue sarcomas, particular emphasis is given to the staging of the diseases and to the important role of local treatment in the survival of these patients. A combination of radiation therapy and surgery is strongly recommended.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510623     DOI: 10.2165/00003495-199447010-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  46 in total

1.  Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease.

Authors:  J J Wang; E Cortes; L F Sinks; J F Holland
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

2.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

3.  Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.

Authors:  G Saeter; T A Alvegård; I Elomaa; A E Stenwig; T Holmström; O P Solheim
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

4.  The effect of local extent of the tumor on prognosis in osteosarcoma.

Authors:  S S Spanier; J J Shuster; R A Vander Griend
Journal:  J Bone Joint Surg Am       Date:  1990-06       Impact factor: 5.284

5.  cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma.

Authors:  J J Ochs; A I Freeman; H O Douglass; D S Higby; E R Mindell; L F Sinks
Journal:  Cancer Treat Rep       Date:  1978-02

6.  Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group.

Authors:  H T Mouridsen; L Bastholt; R Somers; A Santoro; V Bramwell; J H Mulder; A T van Oosterom; J Buesa; H M Pinedo; D Thomas
Journal:  Eur J Cancer Clin Oncol       Date:  1987-10

7.  Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.

Authors:  G Bacci; P Picci; P Ruggieri; M Mercuri; M Avella; R Capanna; A Brach Del Prever; A Mancini; F Gherlinzoni; G Padovani
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

8.  Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma.

Authors:  B E Powers; S J Withrow; D E Thrall; R C Straw; S M LaRue; R L Page; E L Gillette
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

9.  The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli.

Authors:  M Campanacci; G Bacci; F Bertoni; P Picci; A Minutillo; C Franceschi
Journal:  Cancer       Date:  1981-10-01       Impact factor: 6.860

10.  Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54.

Authors:  G Uribe-Botero; W O Russell; W W Sutow; R G Martin
Journal:  Am J Clin Pathol       Date:  1977-05       Impact factor: 2.493

View more
  13 in total

1.  Primary intracerebral osteosarcoma: a case report.

Authors:  G S Bauman; W M Wara; S F Ciricillo; R L Davis; S Zoger; M S Edwards
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 2.  Primary intraventricular osteosarcoma in a 3-year-old boy: report of a case and review of literature.

Authors:  Ahmad Pourrashidi Boshrabadi; Mohammadali Surakiazad; Kourosh Karimi Yarandi; Abbas Amirjamshidi
Journal:  Childs Nerv Syst       Date:  2017-06-16       Impact factor: 1.475

Review 3.  Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

Authors:  Risto S Cvetković; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

5.  Osteosarcoma: mouse models, cell of origin and cancer stem cell.

Authors:  Maria V Guijarro
Journal:  Postdoc J       Date:  2014-02

6.  The kinase Mirk is a potential therapeutic target in osteosarcoma.

Authors:  Cao Yang; Diana Ji; Edward J Weinstein; Edwin Choy; Francis J Hornicek; Kirkham B Wood; Xianzhe Liu; Henry Mankin; Zhenfeng Duan
Journal:  Carcinogenesis       Date:  2009-12-30       Impact factor: 4.944

7.  Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry.

Authors:  Kuan Liu; Peng-cheng Liu; Run Liu; Xing Wu
Journal:  Med Sci Monit Basic Res       Date:  2015-02-09

Review 8.  Animal models in osteosarcoma.

Authors:  Maria V Guijarro; Steven C Ghivizzani; C Parker Gibbs
Journal:  Front Oncol       Date:  2014-07-18       Impact factor: 6.244

9.  Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model.

Authors:  Jian Yang; Weichun Guo; Lu Wang; Ling Yu; Hongjun Mei; Shuo Fang; Peng Ji; Yang Liu; Gaiwei Liu; Qi Song
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

10.  Establishment and Characterization of a Human Small Cell Osteosarcoma Cancer Stem Cell Line: A New Possible In Vitro Model for Discovering Small Cell Osteosarcoma Biology.

Authors:  Gaia Palmini; Roberto Zonefrati; Cecilia Romagnoli; Alessandra Aldinucci; Carmelo Mavilia; Gigliola Leoncini; Alessandro Franchi; Rodolfo Capanna; Maria Luisa Brandi
Journal:  Stem Cells Int       Date:  2016-08-29       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.